C4 Therapeutics, Inc.
NASDAQ:CCCC
Overview | Financials
Company Name | C4 Therapeutics, Inc. |
Symbol | CCCC |
Currency | USD |
Price | 3.87 |
Market Cap | 273,179,430 |
Dividend Yield | 0% |
52-week-range | 3.61 - 11.88 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Andrew J. Hirsch M.B.A. |
Website | https://www.c4therapeutics.com |
An error occurred while fetching data.
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD